RAPT Therapeutics (NASDAQ:RAPT) Receives "Peer Perform" Rating from Wolfe Research

Wolfe Research reissued their peer perform rating on shares of RAPT Therapeutics (NASDAQ:RAPT - Free Report) in a research note published on Tuesday morning, MarketBeat reports.

A number of other equities analysts have also issued reports on the company. Leerink Partnrs lowered RAPT Therapeutics from an outperform rating to a market perform rating in a report on Wednesday, February 21st. HC Wainwright restated a neutral rating on shares of RAPT Therapeutics in a research note on Wednesday, April 10th. Evercore ISI began coverage on shares of RAPT Therapeutics in a research report on Friday, February 16th. They issued an outperform rating for the company. Cantor Fitzgerald downgraded shares of RAPT Therapeutics from an overweight rating to a neutral rating in a research report on Tuesday, February 20th. Finally, Barclays cut shares of RAPT Therapeutics from an overweight rating to an equal weight rating and decreased their price objective for the company from $13.00 to $4.00 in a report on Friday. Nine research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of Hold and an average price target of $24.67.

RAPT Therapeutics Stock Down 9.1 %

RAPT stock traded down $0.40 during mid-day trading on Tuesday, reaching $4.00. The company had a trading volume of 1,245,139 shares, compared to its average volume of 1,156,194. RAPT Therapeutics has a one year low of $3.98 and a one year high of $27.35. The stock has a market capitalization of $139.60 million, a P/E ratio of -1.35 and a beta of 0.52. The stock's 50-day simple moving average is $8.14 and its two-hundred day simple moving average is $15.14.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.05. On average, research analysts forecast that RAPT Therapeutics will post -3.16 EPS for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

A number of hedge funds have recently modified their holdings of RAPT. FMR LLC boosted its position in shares of RAPT Therapeutics by 7.4% in the 3rd quarter. FMR LLC now owns 4,499,293 shares of the company's stock valued at $74,778,000 after purchasing an additional 308,804 shares during the period. Vanguard Group Inc. boosted its holdings in shares of RAPT Therapeutics by 21.2% in the first quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company's stock worth $22,386,000 after buying an additional 436,629 shares during the period. Perceptive Advisors LLC increased its position in shares of RAPT Therapeutics by 11.4% in the fourth quarter. Perceptive Advisors LLC now owns 2,139,950 shares of the company's stock worth $53,178,000 after acquiring an additional 219,292 shares in the last quarter. Braidwell LP raised its holdings in shares of RAPT Therapeutics by 10.0% during the third quarter. Braidwell LP now owns 1,082,512 shares of the company's stock valued at $17,991,000 after acquiring an additional 98,112 shares during the period. Finally, Kingdon Capital Management L.L.C. lifted its position in shares of RAPT Therapeutics by 19.9% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 965,828 shares of the company's stock valued at $24,001,000 after acquiring an additional 160,000 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.